



HAL
open science

Comparison of the materno-fetal transfer of fifteen structurally related bisphenol analogues using an ex vivo human placental perfusion model

Clémence Gely, Marlène Z. Lacroix, Mathieu Morin, Christophe Vayssiere, Véronique V. Gayrard-Troy, Nicole Picard-Hagen

► To cite this version:

Clémence Gely, Marlène Z. Lacroix, Mathieu Morin, Christophe Vayssiere, Véronique V. Gayrard-Troy, et al.. Comparison of the materno-fetal transfer of fifteen structurally related bisphenol analogues using an ex vivo human placental perfusion model. *Chemosphere*, 2021, 276, pp.130213. 10.1016/j.chemosphere.2021.130213 . hal-03196053

HAL Id: hal-03196053

<https://hal.inrae.fr/hal-03196053>

Submitted on 24 Apr 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1 **Comparison of the materno-fetal transfer of fifteen structurally related bisphenol**
2 **analogues using an *ex vivo* human placental perfusion model**

3 Clémence A. Gély^{1,2}, Marlène Z. Lacroix², Mathieu Morin³, Christophe Vayssière^{3,4}, Véronique
4 Gayrard¹, Nicole Picard-Hagen¹

5 ¹ToxAlim (Research Centre in Food Toxicology), Université de Toulouse, INRAE, ENVT,
6 INP-Purpan, UPS, Toulouse, France

7 ²INTHERES, Université de Toulouse, INRAE, ENVT, Toulouse, France

8 ³Department of Obstetrics and Gynecology, Paule de Viguier Hospital, CHU Toulouse,
9 Toulouse, France

10 ⁴UMR 1027 INSERM, Team SPHERE, Université de Toulouse, France.

11

12 Véronique Gayrard: veronique.gayrard@envt.fr; Clémence Gély: clemence.gely@inrae.fr ; Marlène
13 Z. Lacroix: marlene.lacroix@envt.fr, Mathieu Morin: morin.m@chu-toulouse.fr; Nicole Picard-
14 Hagen: nicole.hagen@envt.fr; Christophe Vayssière: vayssiere.c@chu-toulouse.fr.

15 ***Corresponding author:***

16 Email: nicole.hagen@envt.fr

17 UMR1331 Toxalim

18 Ecole Nationale Vétérinaire de Toulouse

19 23 chemin des Capelles, BP 87614

20 31076 Toulouse cedex 3

21 France

22 **Competing financial interests:** The authors declare that they have no actual or potential
23 competing financial interests¹

24

¹ **Abbreviations**

BPS: Bisphenol S; BPA: Bisphenol A; BPE: Bisphenol E; 3-3BPA: 2,2-Bis(4-hydroxy-3-methylphenyl)propane (3-3BPA); BPB: Bisphenol B; BPC: Bis(4-hydroxyphenyl)-2,2-dichloroethylene; BPBP: Bisphenol BP; BPF: Bisphenol F; BPFL: Bisphenol FL; BPZ: Bisphenol Z; BP4-4: 4,4'-Dihydroxybiphenyl; BPAP: Bisphenol AP; BPAF: Bisphenol AF; BPP: Bisphenol P; BPM: Bisphenol M; LOQ: limit of quantification.

BSA: Bovine Serum Albumin; ESI⁻: negative electrospray; IS: Internal Standard; MRM: Multiple Reaction Monitoring; OAT: Organic Anion Transporter; QC: Quality Control; RCR: Relative Concentration Residuals; UHPLC-MS/MS: Ultra-High-Performance Liquid Chromatography method coupled to tandem mass spectrometry¹

25 **Highlights**

- 26 • The efficiency of placental transport differs greatly between bisphenols.
- 27 • BP4-4, BPAP, BPE, BPF, 3-3BPA, BPB, BPA cross placenta by simple diffusion.
- 28 • Materno-fetal transfer of BPFL and BPS is very limited.

29 **Abstract**

30 Regulatory measures and public concerns regarding bisphenol A (BPA) have led to its
31 replacement by a variety of alternatives in consumer products. Due to their structural similarity to
32 BPA, these alternatives are under surveillance, however, for potential endocrine disruption.
33 Understanding the materno-fetal transfer of these BPA-related alternatives across the placenta is
34 therefore crucial to assess prenatal exposure risks.

35 The objective of the study was to assess and compare the placental transfer of a set of 15 selected
36 bisphenols (BPs) (BP 4-4, BPA, BPAF, BPAP, 3-3 BPA, BPB, BPBP, BPC, BPE, BPF, BPFL,
37 BPM, BPP, BPS and BPZ) using the *ex vivo* human placental perfusion model.

38 The UPLC–MS/MS method for simultaneous quantification of these BPs in perfusion media, within
39 a concentration range of 0.003 to 5 μ M, was able to measure placenta transfer rates as low as 0.6
40 % to 4 %. Despite their structural similarities, these BPs differed greatly in placental transport
41 efficiency. The placental transfer rates of BP4-4, BPAP, BPE, BPF, 3-3BPA, BPB, BPA were
42 similar to that of antipyrine, indicating that their main transport mechanism was passive diffusion.
43 By contrast, the placental transfer rates of BPFL and BPS were very limited, and intermediate for
44 BPBP, BPZ, BPC, BPM, BPP and BPAF, suggesting weak diffusional permeability and/or that their
45 passage might involve efflux transport. These placental transfer data will be particularly useful for
46 predicting the fetal exposure of this important class of emerging contaminants.

47

48 **Keywords:** bisphenols, human placental transfer, mixture, endocrine disruptor, Liquid
49 chromatography, Mass spectrometry

50 ***Introduction***

51 Serious concerns regarding widespread human exposure to Bisphenol A (BPA) and its adverse
52 health effects have led to the ban or restriction of BPA production and use in many countries,
53 prompting the development of structural analogues to replace BPA in a variety of industrial
54 products (Chen et al., 2016; Liao and Kannan, 2013; Yang et al., 2014). The list of such BP
55 alternatives is still growing and over 20 BPs, including bisphenols AF, AP, B, F, P, S and Z, are
56 used as monomers in the manufacture of epoxy resin and polycarbonate for many consumer
57 products, such as foodstuffs, personal care products, and paper products (Chen et al., 2016;
58 González et al., 2020; Liao and Kannan, 2014). Given the environmental ubiquity of these BPs,
59 humans are constantly being exposed via dietary intake and daily dermal contact with such
60 products. The increased frequency of detection of BPA alternatives in urine indicates the reality of
61 BPA substitution (Frederiksen et al., 2020; Gyllenhammar et al., 2017; Husøy et al., 2019; Lehmler
62 et al., 2018; Lucarini et al., 2020; Philips et al., 2018; Ye et al., 2015). In particular, a human
63 biomonitoring study revealed the presence of 7 BPs (detection rate: BPA 93%, BPS 89%, BPF
64 12%, BPP 39%, BPZ 18%, BPAF 66% and BPAP 44%) in 283 urine samples collected from
65 children in southern China (Chen et al., 2018).

66 However, little is known about the potential adverse effects of these emerging BPA substitutes and
67 most of the toxicological information is limited to their endocrine disruption potential. Like BPA,
68 these structurally similar phenolic compounds seem to affect hormonal systems (Chen et al., 2016;
69 Kojima et al., 2019; Moreman et al., 2017; Pelch et al., 2019; Rochester and Bolden, 2015;
70 Rosenmai et al., 2014; Siracusa et al., 2018; Usman and Ahmad, 2016; Zhang et al., 2018). The
71 developmental effects of some BPs analogues in mammals, mainly rodents, have been
72 documented in a recent literature review (Pelch et al., 2019). Most studies have only investigated a
73 single BPA analogue, such as BPS, BPAF, BPF or BPE, thereby precluding direct comparisons
74 between them. In addition, the endpoints evaluated in these studies were diverse and included
75 altered hormonal signaling and reproduction (Shi et al. 2018), disruption of mammary gland
76 development (Tucker et al., 2018), behavioral changes (Catanese and Vandenberg, 2016) and

77 metabolic disorder (Mustieles et al., 2020). For example, a study of prenatal *in vivo* exposure to
78 BPS and BPAF showed that such exposure affects the mammary gland of the developing fetus
79 (Tucker et al., 2018). Altogether, these data highlight the vulnerability of the developmental period
80 to exposure to these emerging BPs.

81 Data on human biomonitoring of BP analogues in maternal-cord blood samples remain limited, with
82 most studies focused on only 2 or 3 analogues (Ihde et al., 2018; Liu et al., 2017; Pan et al., 2020;
83 Zhang et al., 2020). Several alternative BPs, including BPS, BPAF, BPE, BPF and BPAP have
84 frequently been detected in the human maternal-fetal-placental unit (Pan et al., 2020), indicating
85 that such contaminants can across the placental barrier. Given their structural diversity, the harmful
86 consequences of BPA substitution for fetal health may be exacerbated if the physicochemical
87 properties of these analogues promote their placental transfer, and thus increase fetal exposure.
88 Understanding the materno-fetal transfer of these BPA alternatives across the placenta is therefore
89 crucial for assessing prenatal exposure risks.

90 To that end, the *ex vivo* perfused human placental cotyledon model, which allows reproduction of
91 the conditions of the third trimester of pregnancy, is the method of choice for studying human
92 placental transfer (Hutson et al., 2011). This model had already been used to quantify the
93 transplacental transfer of BPA (Corbel et al., 2014) and BPS (Grandin et al., 2019) and was
94 therefore used here to investigate the materno-fetal placental transfer of fifteen BPs. We focused
95 on bisphenol 4-4, bisphenol A, bisphenol AF, bisphenol AP, 3-3 bisphenol A, bisphenol B,
96 bisphenol BP, bisphenol C, bisphenol E, bisphenol F, bisphenol FL, bisphenol M, bisphenol P,
97 bisphenol S, and bisphenol Z (Figure 1), because of their occurrence in foodstuffs (Caballero-
98 Casero et al., 2016; Liao and Kannan, 2013), their volume of production (“Search for Chemicals -
99 ECHA,”), their presence in human urine (Chen et al., 2018) and their structural diversity.

100 We chose a cocktail approach because the placenta perfusion method remains a time-consuming
101 experimental method that required some logistic and technical challenges. We first developed and
102 validated an ultra-high-performance liquid chromatography method coupled to tandem mass
103 spectrometry to assay all fifteen BPs simultaneously. To check that the combination of 15 BPs did

104 not interfere with the placental transfer mechanism, we compared the maternal-fetal placental
105 indices of BPA and BPS evaluated with this cocktail approach to those previously determined for
106 these compounds perfused individually using the same model (Corbel et al., 2014; Grandin et al.,
107 2019). This approach, by allowing comparison of the values obtained for a key parameter,
108 placental clearance, should provide new insights for understanding fetal BPs exposure and
109 assessing the hazards of BPA substitution in vulnerable populations, such as the developing fetus.


110

111 **1. Material and methods**


112 The study was designed to evaluate the simultaneous placental transfer of fifteen BPs in the
113 maternal-fetal direction.

114 1.1 Chemicals


115 Bisphenol S (BPS) (purity \geq 98%), Bisphenol A (BPA) (purity \geq 99%), Bisphenol E (BPE) (purity \geq
116 98%), 2,2-Bis(4-hydroxy-3-methylphenyl)propane (3-3BPA) (purity \geq 97%), Bisphenol B (BPB)
117 (purity \geq 98%), Bis(4-hydroxyphenyl)-2,2-dichloroethylene (BPC) (purity \geq 98%), Bisphenol BP
118 (BPBP) (purity \geq 98%), Bisphenol F (BPF) (purity \geq 98%), Bisphenol FL (BPFL) (purity \geq 97%),
119 Bisphenol Z (BPZ) (purity \geq 98%), 4,4'-Dihydroxybiphenyl (BP4-4) (purity \geq 97%), Bisphenol AP
120 (BPAP) (purity \geq 99%), Bisphenol AF (BPAF) (purity \geq 97%), Bisphenol P (BPP) (purity \geq 98%),
121 Bisphenol M (BPM) (purity \geq 99%) (Figure 1) and antipyrine (purity \geq 98%) were purchased from
122 Sigma-Aldrich (Saint-Louis, Missouri, USA).




4,4'-sulfonyldiphenol (**BPS**)
M= 250 g/mol
 CAS : 80-09-1




4,4'-methylenediphenol (**BPF**)
M=200g/mol
 CAS : 620-92-8




4,4'-(propane-2,2-diyl)diphenol (**BPA**)
M=228 g/mol
 CAS : 80-05-7




4,4'-(ethane-1,1-diyl)diphenol (**BPE**)
M=214 g/mol
 CAS : 2081-08-05




4,4'-(2,2-dichloroethene-1,1-diyl)diphenol (**BPC**)
M=280 g/mol
 CAS : 14868-03-2




4,4'-(1-phenylethane-1,1-diyl)diphenol (**BPAP**)
M=290 g/mol
 CAS : 1571-75-1




4,4'-(perfluoropropane-2,2-diyl)diphenol (**BPAF**)
M=336 g/mol
 CAS : 1478-61-1




4,4'-(3-isopropylidene-0-cresol)diphenol (**3-3 BPA**)
M=256 g/mol
 CAS : 79-97-01212




4,4'-(9H-fluorene-9,9-diyl)diphenol (**BPFL**)
M= 250 g/mol
 CAS : 3236-71-3




4,4'-(1,3-phenylenebis(propane-2,2-diyl))diphenol (**BPM**)
M=246 g/mol
 CAS : 13595-25-0




4,4'-(cyclohexane-1,1-diyl)diphenol (**BPZ**)
M=268 g/mol
 CAS : 843-55-0




4,4'-(diphenylmethylene)diphenol (**BPBP**)
M=352 g/mol
 CAS : 1844-01-5



[1,1'-biphenyl]-4,4'-diol (**BP4-4**)
M=186 g/mol
 CAS : 92-88-6



4,4'-(1,4-phenylenebis(propane-2,2-diyl))diphenol (**BPP**)
M=346 g/mol
 CAS : 2167-51-3



4,4'-(butane-2,2-diyl)diphenol (**BPB**)
M=242 g/mol
 CAS : 77-40-7

123

124 Figure 1: Molecular structures of the fifteen BPs

125 Six isotopes-labeled standards, namely, BPAF-d4 (purity \geq 98%), BPAP-d5 (purity \geq 97.5%), BPP-
126 d16 (purity \geq 98%), BPS-d8 (purity \geq 97%), and BPA¹³C₁₂ (purity \geq 98%), used as internal
127 standards, were purchased from Toronto Research Chemicals (Toronto Canada). Methanol and
128 Acetonitrile were LC/MS quality and purchased from Fisher Scientific (Illkirch, France) and acetone
129 was LC quality purchased from Sigma-Aldrich (Saint-Louis, Missouri, USA).

130 All BPs, except BPBP, were dissolved in ethanol at a concentration of 150mM. BPBP was
131 dissolved at 30mM, due to its weak solubility. A solution containing all fifteen BPs was prepared at
132 the same concentration of 7.5mM for each BP, except BPBP (concentration of 1.5mM). The
133 solutions were stored at -20 °C until use. Bovine serum albumin (BSA, Fraction V, purity 100%,
134 Aviva Systems Biology, San Diego, USA) and Earle's Balanced Salt solution were purchased from
135 United States Biological (Salem, MA 01970, United-States). The materials for placental perfusion,
136 including the materials used to prepare solutions, sampling, processing and analysis, were in glass
137 or BPA- and BPS-free plastic containers and the absence of leaching of BPs from the tubing was
138 verified.

139 The absence of binding to the perfusion equipment was checked by comparing the BPs
140 concentrations in the maternal reservoir and in the maternal perfusate circulating in the tubing
141 without the cotyledon (mean ratios between 93 and 103% for the BPs).

142 1.2 Placental perfusion

143 Placentas (519 ± 113 g) were collected from HIV-seronegative women with normal pregnancies
144 following vaginal ($n = 1$) or caesarean ($n = 4$) delivery in the CHU Paule de Viguier, Toulouse,
145 France. The study received institutional approval (DC-2016-2694) and each patient gave written
146 informed consent to participate in the study.

147 Collected placentas were perfused in an open double circuit as previously described (Corbel et al.,
148 2014; Grandin et al., 2019). Perfusion experiments were started within 30 min after delivery.
149 Briefly, after visual confirmation of the vascular integrity of both the maternal and fetal sides, a
150 distal branch of a fetal artery and the associated vein supplying a peripheral cotyledon, were

151 cannulated (Microtube Tygon S54HL, Saint Gobain, Courbevoie, France). The balance between
152 arterial and venous fetal flows was evaluated and placentas with evidence of vascular leakage
153 were discarded (Karttunen et al., 2015). On the maternal side, the perfused area progressively
154 whitened, which allowed visualization of the chosen cotyledon. The cotyledon was placed in the
155 perfusion chamber and maintained at 37°C, with the maternal side upward. Perfusion on the
156 maternal side was subsequently initiated by inserting two catheters into the intervillous space. The
157 fetal and maternal flows were 6 and 12 ml/min, respectively, and the perfusion length was 90 min.
158 The pH was continuously adjusted throughout the perfusion to 7.41 ± 0.022 and 7.23 ± 0.025 for
159 the maternal and fetal perfusion media, respectively. The balance between arterial and venous
160 fetal flows and pressures (between 40 and 60 mm Hg) were monitored throughout the experiment
161 to control the integrity and functionality of the perfusion. Earle medium supplemented with 25 g/L
162 bovine serum albumin (BSA) at 37 °C was used to reflect the physiological plasma protein
163 concentrations at late pregnancy (Larsson et al., 2008). Indeed, some BPs (BPA, BPS, BPF, BPE,
164 BPB, BPM and BPAF) have been shown to bind to plasma albumin (Grumetto, 2019; Luo et al.,
165 2016; Wang et al., 2014; Yang et al., 2017). BSA was used because of its 76.5 % sequence
166 homology with human serum albumin. Antipyrine (20 µg/mL), a reference substance for control of
167 passive diffusion and barrier integrity (Karttunen et al., 2015), and the BPs mixture, were added to
168 the maternal reservoir to study materno-fetal transfer. Because the placental transfer of BPS had
169 been previously reported to be low (Grandin et al., 2019), all BPs (except the weakly soluble
170 BPBP) were used at a final nominal concentration of 5 µM (1 µM for BPBP) to ensure their
171 effective detection in the fetal compartment.

172 Control samples (1 mL) were collected from the fetal and maternal inflow reservoirs before the
173 addition of antipyrine and BPs and from the maternal reservoir after simultaneously adding BPs
174 and antipyrine solutions (time 0) and at 30, 60 and 90 min. During the perfusion, fetal exudates
175 were collected every 5 min and their volumes measured. Maternal exudates were collected
176 immediately after adding the test molecules and every 30 min up to 90 min. At the end of the
177 perfusion, the isolated cotyledon was rinsed with phosphate-buffered saline (pH 7.4) for 15 min.

178 This washing solution was collected. All samples were immediately chilled in ice and centrifuged
179 for 10 min at 3000g and 4 °C to discard placental cells and the supernatant was collected and
180 stored at -20 °C until assayed.

181 1.3 Antipyrine assay

182 Antipyrine concentrations in the perfusion medium were determined by UHPLC coupled with UV
183 detection. Briefly, antipyrine was extracted from the perfusion medium (100 µL of sample) by
184 adding 200µL of 5 % trichloroacetic acid. After mixing and centrifuging (20000 g, 10 min and 4°C),
185 samples were eluted on a C18 column at 0.3 mL/min and 40°C using H₂O / acetonitrile gradient
186 elution with UV detection set at 250 nm. The calibration curve ranged from 0.5 to 50 µg/mL. Data
187 were fitted using a linear model with 1/X (X = concentration) as weighting factor. Blank samples
188 were used to check the absence of contamination during the assays. Accuracy ranged from 87% to
189 103% and the intra- and inter-day coefficients of variation for three concentration levels (0.8, 8 and
190 30 µg/mL) were below 11%. The limit of quantification (LOQ) was validated at 0.5 µg/mL.

191 1.4 Simultaneous quantification of 15 bisphenols in placenta perfusion media

192 1.4.1 Analytical conditions

193 The materno-fetal transfer rates of BPA (Corbel et al., 2014) and BPS (Grandin et al., 2019)
194 previously evaluated on the same perfused placenta model were on average 29 and 3.18 %,
195 respectively. Our objective was to develop a simultaneous assay, without dilution, of the fifteen
196 BPs both in the maternal reservoir and in the fetal outflow perfusate, i.e. with a wide concentration
197 range between 0.05 and 5 µM so as to be able to evaluate materno-fetal transfer rates of BPs
198 ranging between 1% and 40-50%.

199 Samples were assayed by ultra-high performance liquid chromatography coupled to tandem mass
200 spectrometry (Acquity-2D UPLC® Xevo® TQ, Waters, Milford, MA, USA) using the methods
201 previously described by Grandin et al., 2017 and Lacroix et al., 2011. Briefly, BPs were extracted
202 from the perfusion medium (100µL of sample) by adding 200µL of acetone containing internal

203 standards (100 ng/mL). Samples were mixed for 1 min at 10°C and 1400 rpm and centrifuged at
204 20000 g and 4°C for 10 min. Then, 200 µL of supernatant were evaporated to near dryness under
205 nitrogen at 50°C and reconstituted with 200µL of methanol/H₂O: 50/50 (v/v). The BPs were
206 separated on a Raptor Biphenyl column (100 x 2.1 mm; 2.7µm, Restek) at 0.3 mL/min and 40°C
207 using H₂O/ methanol gradient elution.

208 Analytes were detected in negative electrospray (ESI) using multiple reaction monitoring (MRM)
209 mode. The MRM transitions of BPs and IS with their respective cone voltages and collision
210 energies are given in Supplementary Material Table S1.

211 1.4.2 Validation procedure

212 The performance of the method was evaluated according to the European Medicine Agency
213 Guidelines (European Medicine Agency, 2011) for bioanalytical method validation in terms of
214 linearity, intra-day and inter-day repeatability, and sensitivity. Selectivity was tested by comparing
215 five blank perfused media chromatograms with chromatograms at the limits of quantification
216 (LOQ). The LOQs were defined as the lowest concentrations of the calibration curve that could be
217 quantified with less than 20% coefficient of variation (CV%), precision and within an accuracy
218 range of 80–120%.

219 For each BP calibration curve, both simple ($Y = aX + b$) and quadratic ($Y = aX^2 + bX + c$) models
220 were tested after applying appropriate weighting: 1, 1/X and 1/X² (X = nominal concentration).
221 Three approaches were adopted to assess the linearity of the calibration curve: (1) calculation of
222 the relative concentration residuals (RCR%) between the nominal concentration and the
223 concentration obtained with the model, which should be lower than ± 15% (except at the LOQ, ±
224 20%), (2) visual inspection of the residual distribution which should be randomized around the
225 mean and (3) application of a lack-of-fit test to check the goodness-of-fit of the model. Within-day
226 and between-day precisions and accuracies for each BP were calculated on three different days
227 and with six replicates of QC samples at four concentration levels (3, 30, 300 and 1500 ng/mL).

228 1.5 Placental transfer parameters

229 Perfusions in the materno-fetal direction were validated if the transfer rate of antipyrine was above
230 the generally accepted threshold of 20% (Challier et al., 1983; Gavard et al., 2009; Schneider et
231 al., 1972) and remained stable throughout the perfusion. Only the concentrations at steady state
232 for antipyrine and all BPs were used to calculate the transfer rate and the clearance index.

233 As previously described (Corbel et al., 2014; Grandin et al., 2019), the transfer rate was calculated
234 for each steady state time point as the ratio between concentrations in the fetal compartment to
235 concentrations in the maternal compartment. To take the inter placenta variability into account, the
236 clearance index *i.e.* the ratio of the transfer rate of each bisphenol to that of antipyrine, was
237 determined.

238 The mass balance for antipyrine and the 15 BPs was calculated as the ratio of the sum of the
239 quantities of substrate in all the maternal and fetal exudate media and PBS washings to the
240 measured amount of substrate in the maternal reservoir, as previously described (Corbel et al.,
241 2014).

242 1.6 Statistical analysis

243 First, the materno-fetal placenta transfer rate of each bisphenol was compared with that of
244 antipyrine using a Dunnett's multiple comparisons test, with a confidence level of 0.95. Two groups
245 of bisphenols had been identified in a first test: one group containing bisphenols with a transfer rate
246 non significantly different to that of antipyrine and a second group containing bisphenols with a
247 significantly lower transfer rate than that of antipyrine. For each group of bisphenols, the placental
248 clearance indices were compared using an ANOVA followed by a post-hoc Tukey test with a
249 confidence level of 0.95. The statistical analyses were done using the R® software (R
250 development core team, 2009).

251 **2. Results**

252 2.1 Performance of the method for the simultaneous quantification of 15 bisphenols

253 The selectivity of the method was evaluated by comparing the areas of the BPs on five blank
254 samples to the areas at the LOQs. The areas in blank samples were below 20% of that of the
255 LOQs for all BPs except BPAF (29 %) and BPS (43 %). Indeed, BPS was systematically detected
256 in blank media but the areas were always at least two-fold lower than that of their LOQ. However,
257 the method remains suitable for the assessment of BPs placenta transfer since BPs contamination
258 was monitored by injecting blank medium during the sample assays. The LOQs were validated at 1
259 ng/mL for BPAF and BPAP, 5 ng/mL for BP4-4, BPF, BPE, BPA, BPB, BPZ, BPM, BPFL, BPBP,
260 10 ng/mL for BPS and 50 ng/mL for 3-3BPA, BPC and BPP, with intra-day CVs below 21 % and
261 accuracies within 83-119%. Intra- and inter-day precisions were below 22% with accuracy ranging
262 from 85% to 117% for all BPs (Table 1). The calibration curve ranges were established from the
263 BP LOQs up to 2000 ng/mL to ensure placental transfer rate measurements between 1 and 50 %
264 without requiring sample dilutions. The method was therefore suitable for the simultaneous
265 quantification of fifteen BPs in both the maternal reservoir and the fetal outflow perfusate.

Compound	BP4-4	BPS	BPF	BPE	BPA	BPAF	BPB	3-3BPA	BPZ	BPC	BPAP	BPP	BPM	BPFL	BPBP	
Internal Standard	BPA13C12	BPSd8	BPAF-d4	BPAF-d4	BPA13C12	BPAF-d4	BPA13C12	BPAP-d5	BPAP-d5	BPAF-d4	BPAP-d5	BPP-d16	BPAP-d5	BPAP-d5	BPAP-d5	
Model	Linear 1/X ²	Linear 1/X ²	Linear 1/X ²	Linear 1/X	Linear 1/X	Linear 1/X ²	Linear 1/X ²	Linear 1/X	Linear 1/X	Linear 1/X	Linear 1/X	Linear 1/X ²	Quadratic 1/X ²	Quadratic 1/X ²	Quadratic 1/X ²	
LOQ (ng/mL)	5	10	5	5	5	1	5	50	5	50	1	50	5	5	5	
CV intra-day %	QC = 3 ng/mL	-	-	-	-	7	-	-	-	-	12	-	-	-	-	
	QC = 30 ng/mL	14	4	16	13	18	3	10	-	9	-	5	-	15	9	15
	QC = 300 ng/mL	12	3	13	8	11	4	7	9	4	7	2	13	9	8	5
	QC = 1500 ng/mL	14	2	10	11	9	11	11	8	4	4	3	15	11	14	13
CV inter-day %	QC = 3 ng/mL	-	-	-	-	6	-	-	-	-	14	-	-	-	-	
	QC = 30 ng/mL	14	4	15	13	22	3	16	-	11	-	8	-	18	21	15
	QC = 300 ng/mL	15	6	14	7	15	4	12	14	4	17	4	16	15	10	9
	QC = 1500 ng/mL	14	4	14	16	14	6	12	16	4	18	3	12	18	15	14
Accuracy %	QC = 3 ng/mL	-	-	-	-	105	-	-	-	-	109	-	-	-	-	
	QC = 30 ng/mL	97	100	98	95	89	101	109	-	99	-	100	-	117	106	112
	QC = 300 ng/mL	105	102	106	106	96	108	112	103	104	90	101	102	108	113	113
	QC = 1500 ng/mL	114	94	109	97	92	109	97	103	99	85	99	102	90	102	92
LOQ	CV intra-day %	12%	7%	15%	7%	15%	11%	11%	9%	13%	17%	21%	15%	11%	1%	5%
	Accuracy %	114%	105%	113%	99%	106%	109%	100%	119%	116%	94%	111%	108%	83%	94%	103%

267 Table 1: Validation results for the simultaneous quantification of 15 bisphenols in placenta medium.

268 2.2 Placental transfer of the mixture of 15 bisphenols

269 The overall mean antipyrine transfer rate, for all the validated perfusions (n=5), was $31.7 \pm 12.6\%$
270 and conforms closely to values reported previously (Corbel et al., 2014; Grandin et al., 2019;
271 Gavard et al., 2009). The wet weight of the perfused cotyledons was 27 ± 4 g (n=3). The average
272 flow rates were 12.5 ± 1.9 mL/min in the maternal circulation and 5.3 ± 0.7 mL/min in the fetal
273 circulation and remained stable throughout the perfusion. No BPs and no antipyrine were detected
274 at levels above the LOQs in control perfusion medium samples collected from the maternal and
275 fetal exudates before adding the compounds. The mean recovery for all BPs was not significantly
276 different from that of antipyrine ($89 \pm 6.2\%$, range 86%-91%), except for BPE ($77 \pm 6\%$, range:70-
277 84%, $p=0.03$, Dunnett test). This incomplete recovery of BPE could be explained by BPE placental
278 metabolism. But the absence of signal corresponding to the MRM transitions of the 15 bisphenol
279 mono-glucuronides confirms the very limited *in vitro* placental metabolism in this open non-
280 recirculating perfusion model.

281 Table 2 summarizes the materno-fetal placental transfer rate and clearance indices of the perfused
282 mixture of fifteen BPs (at the concentration of 5 μ M, except for BPBP, 1 μ M) and antipyrine (at the
283 concentration of 20 μ M).

284


	n=5	Antipyrine	BPA	BPS	BPF	BPAF	BPB	BPE	BPC	BP4-4	3-3BPA	BPAP	BPBP	BPP	BPM	BPZ	BPFL
Transfer rate ^a (%)	Mean	31.68	25.70	2.45	22.52	16.38	26.45	21.52	12.25	21.13	22.86	18.10	7.99	14.68	14.48	9.87	1.98
	SD	12.64	9.85	0.77	11.10	5.95	9.11	8.86	4.55	9.27	8.75	7.15	2.66	6.68	7.34	3.94	0.70
Placental clearance ^b (mL/min)	Mean	1.671	1.345	0.129	1.164	0.857	1.387	1.115	0.640	1.105	1.196	0.946	0.420	0.770	0.763	0.518	0.105
	SD	0.614	0.467	0.039	0.518	0.284	0.436	0.401	0.222	0.455	0.414	0.341	0.135	0.326	0.367	0.195	0.039
Clearance index ^c	Mean	-	0.813	0.079	0.696	0.522	0.842	0.685	0.392	0.663	0.722	0.570	0.257	0.451	0.444	0.318	0.065
	SD	-	0.063	0.017	0.144	0.072	0.079	0.158	0.074	0.136	0.070	0.062	0.046	0.047	0.148	0.090	0.020

285

286 Table 2: Materno-fetal parameters (clearance, transfer rate and clearance index) of 15 bisphenols perfused as a cocktail. ^aThe ratio of the
287 concentration in the receiving compartment to the concentration in the entrance compartment expressed as a percentage. ^bThe concentration in the
288 receiving compartment multiplied by its flow rate to the concentration in the entrance compartment. ^cThe ratio of the transfer rate of each bisphenol to
289 that of antipyrine

290 Despite their similar phenolic structures, these BPs showed a considerable range of placental
 291 transfer rates. The transfer rates of BP4-4 ($21.13 \pm 9.27\%$), BPAP ($18.10 \pm 7.15\%$), BPE ($21.52 \pm$
 292 8.86%), BPF ($22.52 \pm 11.10\%$), 3-3BPA ($22.86 \pm 8.75\%$), BPB ($26.45 \pm 9.11\%$) and BPA (25.70
 293 $\pm 9.85\%$) were not significantly different to that of freely diffusible antipyrine ($31.68 \pm 12.64\%$). By
 294 contrast, the placental transfer rates of the others were significantly lower than that of antipyrine
 295 ($p < 0.05$, Dunnett's multiple comparisons test) and ranged from 7-16% for BPBP ($7.99 \pm 2.66\%$),
 296 BPZ ($9.87 \pm 3.94\%$), BPC ($12.25 \pm 4.55\%$), BPM ($14.48 \pm 7.34\%$), BPP ($14.68 \pm 6.68\%$) and BPAF
 297 ($16.38 \pm 5.95\%$). In addition, the BPFL and BPS placental transfer rates were 10 and 13-fold lower
 298 than that of BPA, *i.e.*, $1.98 \pm 0.70\%$ and $2.45 \pm 0.77\%$, respectively.

299 Figure 2 depicts the individual values and mean \pm SD of the BP clearance indices. The clearance
 300 indices for BPs ranged from 0.065 to 0.842. In group 1, the clearance indices were very close and
 301 only BPA and BPB had a significantly higher clearance index than BPAP (Tukey test). In group 2,
 302 the clearance indices gradually decreased from 0.522 (BPAF) to 0.257 (BPBP), whereas the
 303 clearance indices of BPFL (0.065) and BPS (0.079) were significantly lower than those of all BPs in
 304 Group 2. The BPBP clearance index was significantly lower than those of BPM, BPP and BPAF
 305 and the BPAF clearance index was significantly higher than that of BPZ.



306

307 Figure 2: Clearance indices of the 15 BPs (individual values (x) and mean \pm SD), corresponding to
308 the ratio of BP-studied placental transfer rate divided by the antipyrine transfer rate.

309 **3. Discussion**

310 Prenatal exposure to BPs may result in adverse effects on sensitive developmental processes. The
311 scarcity of data concerning exposure of the human fetus to BPs analogues highlights the urgent
312 need for a better understanding of the maternal-fetal-placental exchanges of these emerging
313 structurally-related BPs.

314 In the present study, the *ex vivo* perfusion model of the human term placenta was used to examine
315 the placental passage of 15 structurally related BPs. A method for the simultaneous quantification
316 of 15 BPs analogues in the perfusion media was developed in UHPLC-MS/MS with performance
317 fulfilling the acceptability criteria recommended in the EMA guidelines, in terms of sensitivity,
318 precision and accuracy (European Medicines Agency, 2011). This method is suitable for
319 quantifying low materno-fetal placental transfer rates within 0.6-4% depending on the BPs.

320 Antipyrine, a free passive diffusion reference which is not bound to plasma proteins, was used as a
321 reference substance to assess the transfer rates of lipid-soluble xenobiotics (Ala-Kokko et al.,
322 2000). The antipyrine clearances observed in this study (1.06-2.34 mL/min) were close to values
323 reported previously, 2.24 ± 0.68 mL/min and 1.83 ± 0.619 mL/min, respectively (Corbel et al., 2014;
324 Grandin et al., 2019). The clearance of each BP was expressed as a fraction of the antipyrine
325 clearance (clearance index) to overcome inter-placental variability (Challier, 1985), and allow
326 comparisons between different BPs and different experiments.

327 The BPA and BPS clearance indices (0.813 ± 0.063 and 0.079 ± 0.017) evaluated here with a
328 combination of fifteen BPs, did not differ from those determined previously with the same
329 compounds perfused separately (0.813 ± 0.13 and 0.0852 ± 0.0515 , respectively, (Corbel et al.,
330 2014; Grandin et al., 2019), suggesting that the combination of 15 BPs did not interfere with the
331 placental transfer mechanism and thus validated our cocktail approach.

332 Despite the structural similarities of these 15 BPs, the clearance indices for the current data set
333 ranged from 0.065 for BPFL to 0.842 for BPB, indicating considerable differences in the efficiency
334 of BP transport between BPs. The placental transfer rates of BP4-4, BPAP, BPE, BPF, 3-3BPA,

335 BPB, BPA were similar to that of antipyrine, suggesting that exchange of these bisphenols across
336 the placenta mainly involves passive diffusion and is solely limited by the placental blood flow. By
337 contrast, the placental transfer rates for BPFL and BPS were very limited, and intermediate for
338 BPBP, BPZ, BPC, BPM, BPP and BPAF suggesting that the placental transfer of these BPs does
339 not rely solely on weak diffusional permeability but might involve differentially active transport.
340 However, considering the high doses of BPs used, a saturation of the placental transfer cannot be
341 ruled out.

342 In agreement with these findings, previous comparative toxicokinetic results in a pregnant sheep
343 model showed that the materno-fetal transfer of BPS was ten-fold lower than that of BPA
344 (Gauderat et al., 2017; Grandin et al., 2018) and that the feto-maternal total concentrations ratio of
345 BPS was lower than those of BPF and BPA after a single subcutaneous administration of BPS or a
346 mixture of BPA, BPS and BPF (Gingrich et al., 2019). Moreover, in a recent prospective birth
347 cohort (Zhang et al., 2020), the ratio between umbilical cord and maternal total plasma
348 concentrations of BPS was lower (1.11 in 11 pairs) than the ratios for BPA (1.94, n=73) and BPAF
349 (3.26, n=22), which is consistent with a lower placental passage of this BP analogue. However, the
350 human isolated cotyledon model, unlike the *in vivo* model, does not incorporate those nonplacental
351 toxicokinetic factors that determine fetal exposure, such as maternal and fetal metabolism. Thus, it
352 was shown in the pregnant sheep model that despite the low materno-fetal placental transfer of
353 BPS, the accumulation of BPS in the fetal compartment after repeated maternal exposure led to
354 chronic fetal exposure to BPS in a range of concentrations similar to those obtained for BPA
355 (Grandin et al., 2018). Another limitation imposed by this model is that the present results refer to
356 placenta at term and cannot necessarily be extrapolated to earlier stages of gestation. However,
357 due to the placental thickness, the maximal uterine flow and the decrease of certain efflux
358 transporters such as P-glycoprotein at term (Ceckova-Novotna et al., 2006; Joshi et al., 2016), the
359 materno-fetal placental transfer rate at term may be considered as higher than at earlier
360 gestational ages (Syme et al., 2004).

361 The placental transfer process may depend on the physicochemical and molecular properties of
 362 BPs, such as molecular size, lipophilicity (LogP), degree of ionization (pKa) and hydrogen-binding
 363 capacity (Syme et al., 2004, Gedeon and Koren, 2006, Giaginis et al. 2009). In general, neutral
 364 compounds with a molecular weight below 600 Da, high lipid solubility (LogP>1) and few hydrogen
 365 bonding sites have a high potential to freely diffuse across the placenta (Audus, 1999; Pacifici and
 366 Nottoli, 1995). Thus, the physicochemical properties of these 15 BPs (LogP within 2-7, pKa close
 367 to 8.5-9 and MW below 600 Da) would imply that their potential passive diffusion across the
 368 placenta would be high (Table 4). However, this is only true for seven BPs (BPAP, BP4-4, BPE,
 369 BPF, 3-3BPA, BPA and BPB). By contrast, the restricted transplacental permeability of BPBP,
 370 BPZ, BPC, BPM, BPP, BPAF, and, notably of BPS and BPFL, cannot be predicted solely from their
 371 physicochemical properties (Table 3).

	Molecular weight (Da) ^a	pKa ^a acidity constant	log P ^b partition coefficient	percent unbound to plasma proteins (Grumetto, 2019)	Clearance indices ^c (mean ± SD)
BPFL	350.13	9.14	5.59		0.065 ± 0.020
BPS	250.03	8.44	2.15	13.23	0.079 ± 0.017
BPBP	352.15	9.21	6.02		0.257 ± 0.046
BPZ	268.15	9.45	5.00		0.318 ± 0.090
BPC	280.01	9.23	3.95		0.392 ± 0.074
BPM	346.19	9.47	7.04	0.98	0.444 ± 0.148
BPP	346.19	9.49	7.04		0.451 ± 0.047
BPAF	336.06	8.90	5.02	1.10	0.522 ± 0.072
BPAP	290.13	9.36	5.00		0.570 ± 0.062
BP4-4	186.07	9.45	2.52		0.663 ± 0.136
BPE	214.10	9.59	3.18	5.82	0.685 ± 0.158
BPF	200.08	9.66	2.91	7.58	0.696 ± 0.144
3-3BPA	256.15	9.74	4.81		0.722 ± 0.070
BPA	228.12	9.52	3.32	4.09	0.813 ± 0.063
BPB	242.13	9.49	4.44	3.21	0.842 ± 0.079

372 Table 3: Chemical properties of bisphenols and relationship with the clearance index.

373 ^aChemDraw17.1 (Molecular Networks). ^bChemDraw17.1 (ChemPropPro). ^cThe BP-studied
 374 placental transfer rate divided by the antipyrine transfer rate

375

376 The maternal plasma protein binding mechanism limits the rate of transfer across the placenta
377 because only the free fraction of a molecule can diffuse across a cell membrane. A recent study to
378 determine the affinities for human serum albumin of bisphenol A and several of its analogues, both
379 by in vitro biomimetic LC and *in silico* prediction, showed that the interaction was largely non-
380 specific and mainly lipophilicity-driven (Grumetto, 2019). The predicted limited unbound fractions of
381 BPM and BPAF (0.98 and 1.10%, respectively) compared to those of highly diffusible BPs (BPE:
382 5.82%, BPF: 7.58%, BPA: 4.09% and BPB: 3.21 %) are consistent with their differences in
383 placental transfer rate. By contrast, the materno-fetal transfer of BPS is very limited even though its
384 predicted free fraction in serum is relatively high (13.23 %).

385 Alternatively, the materno-fetal transfer of BPS and BPFL might be restricted by the activity of an
386 efflux transporter. Indeed, several ATP-dependent transporters including multi-drug resistant
387 proteins and organic anion transporter (OAT) proteins, predominantly expressed in the
388 syncytiotrophoblast, are involved in the efflux transport of a wide variety of xenobiotics and thereby
389 in protection of the fetus (Syme et al., 2004). They are known to transport BPs compounds (Jin and
390 Audus, 2005; Mørck et al., 2010) and their levels could be altered by bisphenols (Sieppi et al.,
391 2016; Speidel et al., 2018). However, previous data showed that P-glycoprotein is not involved in
392 limiting the materno-fetal placental transfer of BPS (Grandin et al., 2019). Further investigation is
393 required to see if small structural changes in these analogues could influence the binding sites to
394 transporters and thus the mechanism of transplacental transfer.

395 **4. Conclusion**

396 In conclusion, this is the first study to compare the materno-fetal placental transport of fifteen BPs
397 perfused simultaneously through the term placenta, using the human placental perfusion model.
398 These newly-introduced bisphenols present a wide range of placental transfer rates despite their
399 similar molecular structures. Passive diffusion was the main transport mechanism for seven BPs,
400 BP4-4, BPAP, BPE, BPF, 3-3BPA, BPB, BPA. By contrast, the placenta transfer rates for BPFL
401 and BPS were very limited, and intermediate for BPBP, BPZ, BPC, BPM, BPP and BPAF
402 suggesting that their passage across the placenta does not rely solely on weak diffusional

403 permeability but might involve active transport. However, the placental transfer efficiency of these
404 structurally related bisphenols, determined *ex vivo*, cannot be explained by their physico-chemical
405 properties alone. The data obtained for these fifteen bisphenols will be particularly useful for further
406 development of Quantitative Structure-Activity Relationships (QSARs) models to evaluate the
407 relative contributions of physicochemical, molecular and structural properties in the placental
408 transfer of bisphenols in placental process (Giaginis et al., 2009), and predict the placental
409 transport of this important class of emerging contaminants. This could lead to rapid screening and
410 subsequent discarding of endocrine-active BPA substitutes with a high fetal exposure potential.

411

412 ***Acknowledgments***

413 The authors thank N. Deschamps for her assistance and involvement in placenta perfusion.

414

415 **3. References**

- 416 Ala-Kokko, T.I., Myllynen, P., Vähäkangas, K., 2000. Ex vivo perfusion of the human
417 placental cotyledon: implications for anesthetic pharmacology. *Int. J. Obstet. Anesth.*
418 9, 26–38. <https://doi.org/10.1054/ijoa.1999.0312>
- 419 Audus, K.L., 1999. Controlling drug delivery across the placenta. *Eur. J. Pharm. Sci.* 8, 161–
420 165. [https://doi.org/10.1016/S0928-0987\(99\)00031-7](https://doi.org/10.1016/S0928-0987(99)00031-7)
- 421 Caballero-Casero, N., Lunar, L., Rubio, S., 2016. Analytical methods for the determination of
422 mixtures of bisphenols and derivatives in human and environmental exposure
423 sources and biological fluids. A review. *Anal. Chim. Acta* 908, 22–53.
424 <https://doi.org/10.1016/j.aca.2015.12.034>
- 425 Catanese, M.C., Vandenberg, L.N., 2016. Bisphenol S (BPS) alters maternal behavior and
426 brain in mice exposed during pregnancy/lactation and their daughters. *Endocrinology*
427 en.2016-1723. <https://doi.org/10.1210/en.2016-1723>
- 428 Ceckova-Novotna, M., Pavek, P., Staud, F., 2006. P-glycoprotein in the placenta:
429 Expression, localization, regulation and function. *Reprod. Toxicol.* 22, 400–410.
430 <https://doi.org/10.1016/j.reprotox.2006.01.007>
- 431 Challier, J.-C., 1985. Criteria for Evaluating Perfusion Experiments and Presentation of
432 Results, in: Schneider, H., Dancis, J. (Eds.), *Contributions to Gynecology and*
433 *Obstetrics*. S. Karger AG, pp. 32–39. <https://doi.org/10.1159/000410667>
- 434 Challier, J.C., D'Athis, Ph., Guerre-Millo, M., Nandakumaran, M., 1983. Flow-dependent
435 transfer of antipyrine in the human placenta in vitro. *Reprod. Nutr. Dév.* 23, 41–50.
436 <https://doi.org/10.1051/rnd:19830104>
- 437 Chen, D., Kannan, K., Tan, H., Zheng, Z., Feng, Y.-L., Wu, Y., Widelka, M., 2016. Bisphenol
438 Analogues Other Than BPA: Environmental Occurrence, Human Exposure, and
439 Toxicity—A Review. *Environ. Sci. Technol.* 50, 5438–5453.
440 <https://doi.org/10.1021/acs.est.5b05387>
- 441 Chen, Y., Fang, J., Ren, L., Fan, R., Zhang, J., Liu, G., Zhou, L., Chen, D., Yu, Y., Lu, S.,
442 2018. Urinary bisphenol analogues and triclosan in children from south China and
443 implications for human exposure. *Environ. Pollut.* 238, 299–305.
444 <https://doi.org/10.1016/j.envpol.2018.03.031>
- 445 Corbel, T., Gayrard, V., Puel, S., Lacroix, M.Z., Berrebi, A., Gil, S., Viguié, C., Toutain, P.-L.,
446 Picard-Hagen, N., 2014. Bidirectional placental transfer of Bisphenol A and its main
447 metabolite, Bisphenol A-Glucuronide, in the isolated perfused human placenta.
448 *Reprod. Toxicol.* 47, 51–58. <https://doi.org/10.1016/j.reprotox.2014.06.001>
- 449 European Medicines Agency, 2011. Guideline on bioanalytical method validation.
- 450 Frederiksen, H., Nielsen, O., Koch, H.M., Skakkebaek, N.E., Juul, A., Jørgensen, N.,
451 Andersson, A.-M., 2020. Changes in urinary excretion of phthalates, phthalate
452 substitutes, bisphenols and other polychlorinated and phenolic substances in young
453 Danish men; 2009–2017. *Int. J. Hyg. Environ. Health* 223, 93–105.
454 <https://doi.org/10.1016/j.ijheh.2019.10.002>
- 455 Gauderat, G., Picard-Hagen, N., Toutain, P.-L., Servien, R., Viguié, C., Puel, S., Lacroix,
456 M.Z., Corbel, T., Bousquet-Melou, A., Gayrard, V., 2017. Prediction of human
457 prenatal exposure to bisphenol A and bisphenol A glucuronide from an ovine semi-
458 physiological toxicokinetic model. *Sci. Rep.* 7. <https://doi.org/10.1038/s41598-017-15646-5>
- 460 Gavard, L., Beghin, D., Forestier, F., Cayre, Y., Peytavin, G., Mandelbrot, L., Farinotti, R.,
461 Gil, S., 2009. Contribution and limit of the model of perfused cotyledon to the study of
462 placental transfer of drugs. Example of a protease inhibitor of HIV: Nelfinavir. *Eur. J.*
463 *Obstet. Gynecol. Reprod. Biol.* 147, 157–160.
464 <https://doi.org/10.1016/j.ejogrb.2009.08.007>
- 465 Gedeon, C., Koren, G., 2006. Designing Pregnancy Centered Medications: Drugs Which Do
466 Not Cross the Human Placenta☆. *Placenta* 27, 861–868.
467 <https://doi.org/10.1016/j.placenta.2005.09.001>

468 Giaginis, C., Zira, A., Theocharis, S., Tsantili-Kakoulidou, A., 2009. Application of quantitative
469 structure–activity relationships for modeling drug and chemical transport across the
470 human placenta barrier: a multivariate data analysis approach. *J. Appl. Toxicol.* 29,
471 724–733. <https://doi.org/10.1002/jat.1466>

472 Gingrich, J., Pu, Y., Ehrhardt, R., Karthikraj, R., Kannan, K., Veiga-Lopez, A., 2019.
473 Toxicokinetics of bisphenol A, bisphenol S, and bisphenol F in a pregnancy sheep
474 model. *Chemosphere* 220, 185–194.
475 <https://doi.org/10.1016/j.chemosphere.2018.12.109>

476 González, N., Cunha, S.C., Ferreira, R., Fernandes, J.O., Marquès, M., Nadal, M., Domingo,
477 J.L., 2020. Concentrations of nine bisphenol analogues in food purchased from
478 Catalonia (Spain): Comparison of canned and non-canned foodstuffs. *Food Chem.*
479 *Toxicol.* 136, 110992. <https://doi.org/10.1016/j.fct.2019.110992>

480 Grandin, F., Picard-Hagen, N., Gayrard, V., Puel, S., Vigié, C., Toutain, P.-L., Debrauwer,
481 L., Lacroix, M.Z., 2017. Development of an on-line solid phase extraction ultra-high-
482 performance liquid chromatography technique coupled to tandem mass spectrometry
483 for quantification of bisphenol S and bisphenol S glucuronide: Applicability to
484 toxicokinetic investigations. *J. Chromatogr. A* 1526, 39–46.
485 <https://doi.org/10.1016/j.chroma.2017.10.020>

486 Grandin, F.C., Lacroix, M.Z., Gayrard, V., Gauderat, G., Mila, H., Toutain, P.-L., Picard-
487 Hagen, N., 2018. Bisphenol S instead of Bisphenol A: Toxicokinetic investigations in
488 the ovine materno-feto-placental unit. *Environ. Int.* 120, 584–592.
489 <https://doi.org/10.1016/j.envint.2018.08.019>

490 Grandin, F.C., Lacroix, M.Z., Gayrard, V., Vigié, C., Mila, H., de Place, A., Vayssière, C.,
491 Morin, M., Corbett, J., Gayrard, C., Gely, C.A., Toutain, P.-L., Picard-Hagen, N.,
492 2019. Is bisphenol S a safer alternative to bisphenol A in terms of potential fetal
493 exposure? Placental transfer across the perfused human placenta. *Chemosphere*
494 221, 471–478. <https://doi.org/10.1016/j.chemosphere.2019.01.065>

495 Grumetto, L., 2019. Scrutinizing the interactions between bisphenol analogues and plasma
496 proteins_ Insights from biomimetic liquid chromatography, molecular docking
497 simulations and in silico predictions. *Environ. Toxicol. Pharmacol.* 7.

498 Gyllenhammar, I., Glynn, A., Jönsson, B.A.G., Lindh, C.H., Darnerud, P.O., Svensson, K.,
499 Lignell, S., 2017. Diverging temporal trends of human exposure to bisphenols and
500 plastizisers, such as phthalates, caused by substitution of legacy EDCs? *Environ.*
501 *Res.* 153, 48–54. <https://doi.org/10.1016/j.envres.2016.11.012>

502 Husøy, T., Andreassen, M., Hjertholm, H., Carlsen, M.H., Norberg, N., Sprong, C.,
503 Papadopoulou, E., Sakhi, A.K., Sabaredzovic, A., Dirven, H.A.A.M., 2019. The
504 Norwegian biomonitoring study from the EU project EuroMix: Levels of phenols and
505 phthalates in 24-hour urine samples and exposure sources from food and personal
506 care products. *Environ. Int.* 132, 105103. <https://doi.org/10.1016/j.envint.2019.105103>

507 Hutson, J.R., Garcia-Bournissen, F., Davis, A., Koren, G., 2011. The Human Placental
508 Perfusion Model: A Systematic Review and Development of a Model to Predict In
509 Vivo Transfer of Therapeutic Drugs. *Clin. Pharmacol. Ther.* 90, 67–76.
510 <https://doi.org/10.1038/clpt.2011.66>

511 Ihde, E.S., Zamudio, S., Loh, J.M., Zhu, Y., Woytanowski, J., Rosen, L., Liu, M., Buckley, B.,
512 2018. Application of a novel mass spectrometric (MS) method to examine exposure
513 to Bisphenol-A and common substitutes in a maternal fetal cohort. *Hum. Ecol. Risk*
514 *Assess. Int. J.* 24, 331–346. <https://doi.org/10.1080/10807039.2017.1381831>

515 Jin, H., Audus, K.L., 2005. Effect of bisphenol A on drug efflux in BeWo, a human
516 trophoblast-like cell line. *Placenta* 26, S96–S103.
517 <https://doi.org/10.1016/j.placenta.2005.01.016>

518 Joshi, A.A., Vaidya, S.S., St-Pierre, M.V., Mikheev, A.M., Desino, K.E., Nyandege, A.N.,
519 Audus, K.L., Unadkat, J.D., Gerk, P.M., 2016. Placental ABC Transporters: Biological
520 Impact and Pharmaceutical Significance. *Pharm. Res.* 33, 2847–2878.
521 <https://doi.org/10.1007/s11095-016-2028-8>

522 Karttunen, V., Sahlman, H., Repo, J.K., Woo, C.S.J., Myöhänen, K., Myllynen, P.,
523 Vähäkangas, K.H., 2015. Criteria and challenges of the human placental perfusion –
524 Data from a large series of perfusions. *Toxicol. In Vitro* 29, 1482–1491.
525 <https://doi.org/10.1016/j.tiv.2015.06.001>

526 Kojima, H., Takeuchi, S., Sanoh, S., Okuda, K., Kitamura, S., Uramaru, N., Sugihara, K.,
527 Yoshinari, K., 2019. Profiling of bisphenol A and eight its analogues on transcriptional
528 activity T via human nuclear receptors 8.

529 Lacroix, M.Z., Puel, S., Collet, S.H., Corbel, T., Picard-Hagen, N., Toutain, Pl., Viguié, C.,
530 Gayraud, V., 2011. Simultaneous quantification of bisphenol A and its glucuronide
531 metabolite (BPA-G) in plasma and urine: Applicability to toxicokinetic investigations.
532 *Talanta* 85, 2053–2059. <https://doi.org/10.1016/j.talanta.2011.07.040>

533 Larsson, A., Palm, M., Hansson, L.-O., Axelsson, O., 2008. Reference values for clinical
534 chemistry tests during normal pregnancy. *BJOG Int. J. Obstet. Gynaecol.* 115, 874–
535 881. <https://doi.org/10.1111/j.1471-0528.2008.01709.x>

536 Lehmler, H.-J., Liu, B., Gadogbe, M., Bao, W., 2018. Exposure to Bisphenol A, Bisphenol F,
537 and Bisphenol S in U.S. Adults and Children: The National Health and Nutrition
538 Examination Survey 2013–2014. *ACS Omega* 3, 6523–6532.
539 <https://doi.org/10.1021/acsomega.8b00824>

540 Liao, C., Kannan, K., 2014. A Survey of Alkylphenols, Bisphenols, and Triclosan in Personal
541 Care Products from China and the United States. *Arch. Environ. Contam. Toxicol.* 67,
542 50–59. <https://doi.org/10.1007/s00244-014-0016-8>

543 Liao, C., Kannan, K., 2013. Concentrations and Profiles of Bisphenol A and Other Bisphenol
544 Analogues in Foodstuffs from the United States and Their Implications for Human
545 Exposure. *J. Agric. Food Chem.* 61, 4655–4662. <https://doi.org/10.1021/jf400445n>

546 Liu, J., Li, J., Wu, Y., Zhao, Y., Luo, F., Li, S., Yang, L., Moez, E.K., Dinu, I., Martin, J.W.,
547 2017. Bisphenol A Metabolites and Bisphenol S in Paired Maternal and Cord Serum.
548 *Environ. Sci. Technol.* 51, 2456–2463. <https://doi.org/10.1021/acs.est.6b05718>

549 Lucarini, F., Krasniqi, T., Bailat Rosset, G., Roth, N., Hopf, N.B., Broillet, M.-C., Staedler, D.,
550 2020. Exposure to New Emerging Bisphenols Among Young Children in Switzerland.
551 *Int. J. Environ. Res. Public Health* 17, 4793. <https://doi.org/10.3390/ijerph17134793>

552 Luo, H., Li, C., Fang, H., Wang, X., 2016. Comparative study of the interactions between
553 bisphenol analogues and serum albumins by electrospray mass spectrometry and
554 fluorescence spectroscopy: Interactions between bisphenol analogues and serum
555 albumins. *Rapid Commun. Mass Spectrom.* 30, 162–167.
556 <https://doi.org/10.1002/rcm.7633>

557 Mørck, T.J., Sorda, G., Bechi, N., Rasmussen, B.S., Nielsen, J.B., Ietta, F., Rytting, E.,
558 Mathiesen, L., Paulesu, L., Knudsen, L.E., 2010. Placental transport and in vitro
559 effects of Bisphenol A. *Reprod. Toxicol.* 30, 131–137.
560 <https://doi.org/10.1016/j.reprotox.2010.02.007>

561 Moreman, J., Lee, O., Trznadel, M., David, A., Kudoh, T., Tyler, C.R., 2017. Acute Toxicity,
562 Teratogenic, and Estrogenic Effects of Bisphenol A and Its Alternative Replacements
563 Bisphenol S, Bisphenol F, and Bisphenol AF in Zebrafish Embryo-Larvae. *Environ.*
564 *Sci. Technol.* 51, 12796–12805. <https://doi.org/10.1021/acs.est.7b03283>

565 Mustieles, V., D’Cruz, S.C., Couderq, S., Rodríguez-Carrillo, A., Fini, J.-B., Hofer, T.,
566 Steffensen, I.-L., Dirven, H., Barouki, R., Olea, N., Fernández, M.F., David, A., 2020.
567 Bisphenol A and its analogues: A comprehensive review to identify and prioritize
568 effect biomarkers for human biomonitoring. *Environ. Int.* 144, 105811.
569 <https://doi.org/10.1016/j.envint.2020.105811>

570 Pacifici, G.M., Nottoli, R., 1995. Placental Transfer of Drugs Administered to the Mother: *Clin.*
571 *Pharmacokinet.* 28, 235–269. <https://doi.org/10.2165/00003088-199528030-00005>

572 Pan, Y., Deng, M., Li, J., Du, B., Lan, S., Liang, X., Zeng, L., 2020. Occurrence and Maternal
573 Transfer of Multiple Bisphenols, Including an Emerging Derivative with Unexpectedly
574 High Concentrations, in the Human Maternal–Fetal–Placental Unit. *Environ. Sci.*
575 *Technol.* 54, 3476–3486. <https://doi.org/10.1021/acs.est.0c00206>

576 Pelch, K., Wignall, J.A., Goldstone, A.E., Ross, P.K., Blain, R.B., Shapiro, A.J., Holmgren,
577 S.D., Hsieh, J.-H., Svoboda, D., Auerbach, S.S., Parham, F.M., Masten, S.A., Walker,
578 V., Rooney, A., Thayer, K.A., 2019. A scoping review of the health and toxicological
579 activity of bisphenol A (BPA) structural analogues and functional alternatives.
580 *Toxicology* 424, 152235. <https://doi.org/10.1016/j.tox.2019.06.006>
581 Philips, E.M., Kahn, L.G., Jaddoe, V.W.V., Shao, Y., Asimakopoulos, A.G., Kannan, K.,
582 Steegers, E.A.P., Trasande, L., 2018. First Trimester Urinary Bisphenol and
583 Phthalate Concentrations and Time to Pregnancy: A Population-Based Cohort
584 Analysis. *J. Clin. Endocrinol. Metab.* 103, 3540–3547. <https://doi.org/10.1210/jc.2018-00855>
585
586 Rochester, J.R., Bolden, A.L., 2015. Bisphenol S and F: A Systematic Review and
587 Comparison of the Hormonal Activity of Bisphenol A Substitutes. *Environ. Health*
588 *Perspect.* <https://doi.org/10.1289/ehp.1408989>
589 Rosenmai, A.K., Dybdahl, M., Pedersen, M., Alice van Vugt-Lussenburg, B.M., Wedebye,
590 E.B., Taxvig, C., Vinggaard, A.M., 2014. Are Structural Analogues to Bisphenol A
591 Safe Alternatives? *Toxicol. Sci.* 139, 35–47. <https://doi.org/10.1093/toxsci/kfu030>
592 Schneider, H., Panigel, M., Dancis, J., 1972. Transfer across the perfused human placenta of
593 antipyrine, sodium, and leucine. *Am. J. Obstet. Gynecol.* 114, 822–828.
594 [https://doi.org/10.1016/0002-9378\(72\)90909-X](https://doi.org/10.1016/0002-9378(72)90909-X)
595 Search for Chemicals - ECHA [WWW Document], n.d. URL [https://echa.europa.eu/fr/search-](https://echa.europa.eu/fr/search-for-chemicals?p_p_id=disssimplesearch_WAR_dissearchportlet&p_p_lifecycle=0&_disssimplesearch_WAR_dissearchportlet_searchOccurred=true&_disssimplesearch_WAR_dissearchportlet_sessionCriteriaId=disSimpleSearchSessionParam101401602581767544)
596 [for-](https://echa.europa.eu/fr/search-for-chemicals?p_p_id=disssimplesearch_WAR_dissearchportlet&p_p_lifecycle=0&_disssimplesearch_WAR_dissearchportlet_searchOccurred=true&_disssimplesearch_WAR_dissearchportlet_sessionCriteriaId=disSimpleSearchSessionParam101401602581767544)
597 [chemicals?p_p_id=disssimplesearch_WAR_dissearchportlet&p_p_lifecycle=0&_disssimplesearch_WAR_dissearchportlet_searchOccurred=true&_disssimplesearch_WA](https://echa.europa.eu/fr/search-for-chemicals?p_p_id=disssimplesearch_WAR_dissearchportlet&p_p_lifecycle=0&_disssimplesearch_WAR_dissearchportlet_searchOccurred=true&_disssimplesearch_WAR_dissearchportlet_sessionCriteriaId=disSimpleSearchSessionParam101401602581767544)
598 [R_dissearchportlet_sessionCriteriaId=disSimpleSearchSessionParam1014016025](https://echa.europa.eu/fr/search-for-chemicals?p_p_id=disssimplesearch_WAR_dissearchportlet&p_p_lifecycle=0&_disssimplesearch_WAR_dissearchportlet_searchOccurred=true&_disssimplesearch_WAR_dissearchportlet_sessionCriteriaId=disSimpleSearchSessionParam101401602581767544)
599 [81767544](https://echa.europa.eu/fr/search-for-chemicals?p_p_id=disssimplesearch_WAR_dissearchportlet&p_p_lifecycle=0&_disssimplesearch_WAR_dissearchportlet_searchOccurred=true&_disssimplesearch_WAR_dissearchportlet_sessionCriteriaId=disSimpleSearchSessionParam101401602581767544) (accessed 10.13.20).
600
601 Shi, M., Sekulovski, N., MacLean, J.A., Hayashi, K., 2018. Prenatal Exposure to Bisphenol A
602 Analogues on Male Reproductive Functions in Mice. *Toxicol. Sci.* 163, 620–631.
603 <https://doi.org/10.1093/toxsci/kfy061>
604 Sieppi, E., Vähäkangas, K., Rautio, A., Ietta, F., Paulesu, L., Myllynen, P., 2016. The
605 xenoestrogens, bisphenol A and para-nonylphenol, decrease the expression of the
606 ABCG2 transporter protein in human term placental explant cultures. *Mol. Cell.*
607 *Endocrinol.* 429, 41–49. <https://doi.org/10.1016/j.mce.2016.03.034>
608 Siracusa, J.S., Yin, L., Measel, E., Liang, S., Yu, X., 2018. Effects of bisphenol A and its
609 analogs on reproductive health: A mini review. *Reprod. Toxicol.* 79, 96–123.
610 <https://doi.org/10.1016/j.reprotox.2018.06.005>
611 Speidel, J.T., Xu, M., Abdel-Rahman, S.Z., 2018. Bisphenol A (BPA) and bisphenol S (BPS)
612 alter the promoter activity of the ABCB1 gene encoding P-glycoprotein in the human
613 placenta in a haplotype-dependent manner. *Toxicol. Appl. Pharmacol.* 359, 47–54.
614 <https://doi.org/10.1016/j.taap.2018.09.022>
615 Syme, M.R., Paxton, J.W., Keelan, J.A., 2004. Drug Transfer and Metabolism by the Human
616 Placenta: *Clin. Pharmacokinet.* 43, 487–514. [https://doi.org/10.2165/00003088-](https://doi.org/10.2165/00003088-200443080-00001)
617 [200443080-00001](https://doi.org/10.2165/00003088-200443080-00001)
618 Tucker, D.K., Hayes Bouknight, S., Brar, S.S., Kissling, G.E., Fenton, S.E., 2018. Evaluation
619 of Prenatal Exposure to Bisphenol Analogues on Development and Long-Term
620 Health of the Mammary Gland in Female Mice. *Environ. Health Perspect.* 126,
621 087003. <https://doi.org/10.1289/EHP3189>
622 Usman, A., Ahmad, M., 2016. From BPA to its analogues: Is it a safe journey? *Chemosphere*
623 158, 131–142. <https://doi.org/10.1016/j.chemosphere.2016.05.070>
624 Wang, Y.-Q., Zhang, H.-M., Cao, J., Tang, B.-P., 2014. Binding of a new bisphenol analogue,
625 bisphenol S to bovine serum albumin and calf thymus DNA. *J. Photochem. Photobiol.*
626 *B* 138, 182–190. <https://doi.org/10.1016/j.jphotobiol.2014.06.002>
627 Yang, H., Huang, Y., Liu, J., Tang, P., Sun, Q., Xiong, X., Tang, B., He, J., Li, H., 2017.
628 Binding modes of environmental endocrine disruptors to human serum albumin:
629 insights from STD-NMR, ITC, spectroscopic and molecular docking studies. *Sci. Rep.*
630 7, 11126. <https://doi.org/10.1038/s41598-017-11604-3>

631 Yang, Yunjia, Lu, L., Zhang, J., Yang, Yi, Wu, Y., Shao, B., 2014. Simultaneous
632 determination of seven bisphenols in environmental water and solid samples by liquid
633 chromatography–electrospray tandem mass spectrometry. *J. Chromatogr. A* 1328,
634 26–34. <https://doi.org/10.1016/j.chroma.2013.12.074>
635 Ye, X., Wong, L.-Y., Kramer, J., Zhou, X., Jia, T., Calafat, A.M., 2015. Urinary
636 Concentrations of Bisphenol A and Three Other Bisphenols in Convenience Samples
637 of U.S. Adults during 2000–2014. *Environ. Sci. Technol.* 49, 11834–11839.
638 <https://doi.org/10.1021/acs.est.5b02135>
639 Zhang, B., He, Y., Zhu, H., Huang, X., Bai, X., Kannan, K., Zhang, T., 2020. Concentrations
640 of bisphenol A and its alternatives in paired maternal–fetal urine, serum and amniotic
641 fluid from an e-waste dismantling area in China. *Environ. Int.* 136, 105407.
642 <https://doi.org/10.1016/j.envint.2019.105407>
643 Zhang, Y.-F., Ren, X.-M., Li, Y.-Y., Yao, X.-F., Li, C.-H., Qin, Z.-F., Guo, L.-H., 2018.
644 Bisphenol A alternatives bisphenol S and bisphenol F interfere with thyroid hormone
645 signaling pathway in vitro and in vivo. *Environ. Pollut.* 237, 1072–1079.
646 <https://doi.org/10.1016/j.envpol.2017.11.027>
647

648


649 Figure legends

650 Figure 1: Molecular structures of the fifteen BPs

651 Figure 2: Clearance indices of the 15 BPs (individual values (x) and mean \pm SD), corresponding to
652 the ratio of the transfer rate of each bisphenol to that of antipyrine.

653

654



Placental transfer efficiencies